Narrative review highlights diagnostic and management challenges for surgeons treating carpal tunnel syndrome in patients with amyloidosis, indicating gaps in current practices.
In the past decade, hand and upper-extremity surgeons have become increasingly aware of the relationship between carpal tunnel syndrome and cardiac amyloidosis.Recent advances in medical management of cardiac amyloidosis in the form of disease-modifying therapies that improve survival have aided decreasing morbidity and in some cases, hand surgeons can detect evidence of amyloid deposition prior to clinical manifestations of cardiac disease.Despite improvements in biopsy techniques and analysis, there remain a number of controversies related to this condition that directly impact upperextremity surgeons.At present, the number needed to screen for biopsy procedures during carpal tunnel release remains poorly defined relative to routine cancer screening protocols and there are a paucity of prior investigations assessing the costs associated with biopsy during carpal tunnel release.This narrative review aims to provide an update on diagnostic and management considerations for hand surgeons evaluating patients with carpal tunnel syndrome.
No takes yet. Share an insight, caveat, or question.
Laridaen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: